LIVIVO - Search results -

Search results

Result 1 - 7 of total 7

Search options

Article ; Online: Impact of COVID-19 on pre-existing liver disease.

Abdo-Francis, Juan M / Moreno-Alcantar, Rosalba / Pérez-Hernández, José L / Remes-Troche, José M / Velasco, Antonio Velarde-Ruiz / Cerda-Reyes, Eira / Tijera, Fátima Higuera-de la / Castro-Narro, Graciela

Cirugia y cirujanos

2024 Volume 92, Issue 1, Page(s) 131–136

Abstract: Patients with chronic liver disease of any etiology who become infected with SARS-CoV-2 have been found to have a higher risk of mortality compared to those patients who do not have chronic liver disease. A literature review was conducted in the ... ...

Title translation	Impacto de COVID-19 en enfermedad hepatica pre-existente.
Abstract	Patients with chronic liver disease of any etiology who become infected with SARS-CoV-2 have been found to have a higher risk of mortality compared to those patients who do not have chronic liver disease. A literature review was conducted in the relationship between COVID 19 and preexistence of liver disease. The proportion of COVID-19 patients with abnormal liver function on admission ranged from 40 % to 75 % and the proportion with liver injury was close to 30%. Current studies show an important association between preexisting liver disease and COVID-19. The presence of cirrhosis is now an independent predictor of severity for COVID-19 and prolonged hospitalization in this group of patients. Patients with cirrhosis have a higher mortality rate, and this rate rises with increasing severity.
MeSH term(s)	Humans ; COVID-19/complications ; SARS-CoV-2 ; Liver Cirrhosis/complications ; Liver Diseases/complications
Language	English
Publishing date	2024-03-27
Publishing country	Mexico
Document type	Review ; Journal Article
ZDB-ID	730699-4
ISSN	2444-054X ; 0009-7411
ISSN (online)	2444-054X
ISSN	0009-7411
DOI	10.24875/CIRU.23000409
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 797: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: PROTON PUMP INHIBITORS INCREASE THE OVERALL RISK OF DEVELOPING BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS.

Lázaro-Pacheco, Illce B / Servín-Caamaño, Alfredo I / Pérez-Hernández, José L / Rojas-Loureiro, Gabriela / Servín-Abad, Luis / Tijera, Fátima Higuera-DE LA

Arquivos de gastroenterologia

2018 Volume 55, Issue 1, Page(s) 28–32

Abstract: Background: Acid suppression has been associated with adverse events; such as, enteric infections. Proton pump inhibitors (PPI) are frequently prescribed in patients with cirrhosis, but is unclear if PPI are associated with the development of bacterial ... ...

Abstract	Background: Acid suppression has been associated with adverse events; such as, enteric infections. Proton pump inhibitors (PPI) are frequently prescribed in patients with cirrhosis, but is unclear if PPI are associated with the development of bacterial infections in these patients. Objective: To assess the impact of PPI intake on the development of bacterial, viral and fungal infections in patients with cirrhosis. Methods: An observational, retrospective, historic cohort study. The exposed cohort included patients with cirrhosis with chronic use of PPI. The non-exposed cohort had not been using PPI. The follow-up period was 3 years, searching in the medical records for any events of bacterial infection confirmed by bacteriological culture. Results: One hundred and thirteen patients met the selection criteria, 44 (39%) had chronic use of PPI; of them, 28 (63.6%) patients had not a clear clinical indication to justify the prescription of PPI. Twenty four (21.2%) patients developed bacterial infections during the follow-up period. In the univariate analysis, decompensated cirrhosis (Child B/C), presence of ascites, history of variceal bleeding, and chronic consumption of PPI were risk factors related to the development of infections. But, in the adjusted multivariate analysis only the chronic use of PPI was associated with development of infections (RR=3.6; 95% CI=1.1-12.3; P=0.04). Conclusion: There is an over-prescription of PPI without a justified clinical indication. The long-term consumption of PPI in patients with cirrhosis is associated with the development of bacterial infections; therefore these drugs must be carefully prescribed in this specific population.
MeSH term(s)	Aged ; Analysis of Variance ; Bacterial Infections/etiology ; Drug Prescriptions/statistics & numerical data ; Female ; Follow-Up Studies ; Humans ; Inappropriate Prescribing/statistics & numerical data ; Liver Cirrhosis/drug therapy ; Liver Cirrhosis/microbiology ; Male ; Middle Aged ; Proton Pump Inhibitors/adverse effects ; Retrospective Studies ; Risk Assessment ; Risk Factors
Chemical Substances	Proton Pump Inhibitors
Language	English
Publishing date	2018-01
Publishing country	Brazil
Document type	Journal Article ; Observational Study
ZDB-ID	137743-7
ISSN	1678-4219 ; 0004-2803
ISSN (online)	1678-4219
ISSN	0004-2803
DOI	10.1590/S0004-2803.201800000-09
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 450: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The Age-AST-D Dimer (AAD) Regression Model Predicts Severe COVID-19 Disease.

Higuera-de-la-Tijera, Fátima / Servín-Caamaño, Alfredo / Reyes-Herrera, Daniel / Flores-López, Argelia / Robiou-Vivero, Enrique J A / Martínez-Rivera, Felipe / Galindo-Hernández, Victor / Rosales-Salyano, Victor H / Casillas-Suárez, Catalina / Chapa-Azuela, Oscar / Chávez-Morales, Alfonso / Jiménez-Bobadilla, Billy / Hernández-Medel, María L / Orozco-Zúñiga, Benjamín / Zacarías-Ezzat, Jed R / Camacho, Santiago / Pérez-Hernández, José L

Disease markers

2021 Volume 2021, Page(s) 6658270

Abstract: Aim: Coronavirus disease (COVID-19) ranges from mild clinical phenotypes to life-threatening conditions like severe acute respiratory syndrome (SARS). It has been suggested that early liver injury in these patients could be a risk factor for poor ... ...

Abstract	Aim: Coronavirus disease (COVID-19) ranges from mild clinical phenotypes to life-threatening conditions like severe acute respiratory syndrome (SARS). It has been suggested that early liver injury in these patients could be a risk factor for poor outcome. We aimed to identify early biochemical predictive factors related to severe disease development with intensive care requirements in patients with COVID-19. Methods: Data from COVID-19 patients were collected at admission time to our hospital. Differential biochemical factors were identified between seriously ill patients requiring intensive care unit (ICU) admission (ICU patients) versus stable patients without the need for ICU admission (non-ICU patients). Multiple linear regression was applied, then a predictive model of severity called Results: Derivation cohort: from 166 patients included, there were 27 (16.3%) ICU patients that showed higher levels of liver injury markers ( Conclusions: The elevation of AST (a possible marker of early liver injury) along with DD and age efficiently predict early (at admission time) probability of ICU admission during the clinical course of COVID-19. The AAD model can improve the comprehensive management of COVID-19 patients, and it could be useful as a triage tool to early classify patients with a high risk of developing a severe clinical course of the disease.
MeSH term(s)	Adult ; Aspartate Aminotransferases/chemistry ; COVID-19/pathology ; COVID-19/therapy ; COVID-19/virology ; Cohort Studies ; Dimerization ; Female ; Humans ; Intensive Care Units ; Male ; Middle Aged ; SARS-CoV-2/isolation & purification ; Severity of Illness Index
Chemical Substances	Aspartate Aminotransferases (EC 2.6.1.1)
Language	English
Publishing date	2021-03-23
Publishing country	United States
Document type	Journal Article
ZDB-ID	604951-5
ISSN	1875-8630 ; 0278-0240
ISSN (online)	1875-8630
ISSN	0278-0240
DOI	10.1155/2021/6658270
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1856: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Einzelsignatur: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.

Higuera-de-la-Tijera, Fátima / Servín-Caamaño, Alfredo I / Salas-Gordillo, Francisco / Pérez-Hernández, José L / Abdo-Francis, Juan M / Camacho-Aguilera, Jaime / Alla, Sai N / Jiménez-Ponce, Fiacro

Canadian journal of gastroenterology & hepatology

2018 Volume 2018, Page(s) 3015891

Abstract: Background and aim: Variceal bleeding is the second most important precipitating factor related to the development of episodic hepatic encephalopathy; but to date there are no recommendations to prevent this complication. The aim of this study was to ... ...

Abstract	Background and aim: Variceal bleeding is the second most important precipitating factor related to the development of episodic hepatic encephalopathy; but to date there are no recommendations to prevent this complication. The aim of this study was to compare if primary prophylaxis with lactulose or L-ornithine L-aspartate or rifaximin, in cirrhotic patients with variceal bleeding, is better than placebo for avoiding the development of hepatic encephalopathy. Methods: A randomized, double-blind, placebo-controlled clinical trial (ClinicalTrials.gov identifier: NCT02158182) which included cirrhotic patients with variceal bleeding, without minimal or clinical hepatic encephalopathy at admission. Findings: 87 patients were randomized to one of four groups. The basal characteristics were similar between groups. Comparatively with placebo, the frequency with regard to the development of hepatic encephalopathy was as follows: lactulose (54.5% versus 27.3%; OR = 0.3, 95% CI 0.09-1.0; Conclusions: Antiammonium drugs, particularly L-ornithine L-aspartate and rifaximin, proved to be effective in preventing the development of hepatic encephalopathy in those cirrhotic patients with variceal bleeding.
MeSH term(s)	Acute Disease ; Adult ; Dipeptides/adverse effects ; Dipeptides/therapeutic use ; Double-Blind Method ; Esophageal and Gastric Varices/etiology ; Female ; Gastrointestinal Agents/administration & dosage ; Gastrointestinal Agents/therapeutic use ; Gastrointestinal Hemorrhage/etiology ; Hepatic Encephalopathy/etiology ; Hepatic Encephalopathy/prevention & control ; Humans ; Lactulose/administration & dosage ; Lactulose/therapeutic use ; Liver Cirrhosis/complications ; Male ; Middle Aged ; Rifaximin/adverse effects ; Rifaximin/therapeutic use
Chemical Substances	Dipeptides ; Gastrointestinal Agents ; Lactulose (4618-18-2) ; ornithylaspartate (JA08T3B97O) ; Rifaximin (L36O5T016N)
Language	English
Publishing date	2018-07-10
Publishing country	Egypt
Document type	Journal Article ; Randomized Controlled Trial
ZDB-ID	2762182-0
ISSN	2291-2797 ; 1916-7237 ; 0835-7900
ISSN (online)	2291-2797 ; 1916-7237
ISSN	0835-7900
DOI	10.1155/2018/3015891
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2360: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America.

Farias, Alberto Queiroz / Curto Vilalta, Anna / Momoyo Zitelli, Patricia / Pereira, Gustavo / Goncalves, Luciana L / Torre, Aldo / Diaz, Juan Manuel / Gadano, Adrian C / Mattos, Angelo Z / Mendes, Liliana S C / Alvares-da-Silva, Mario R / Bittencourt, Paulo L / Benitez, Carlos / Couto, Claudia Alves / Mendizabal, Manuel / Toledo, Claudio L / Mazo, Daniel F C / Castillo Barradas, Mauricio / Uson Raposo, Eva M /

Padilla-Machaca, P Martín / Zarela Lozano Miranda, Adelina / Malé-Velázquez, René / Castro Lyra, André / Dávalos-Moscol, Milagros B / Pérez Hernández, José L / Ximenes, Rafael O / Faria Silva, Giovanni / Beltrán-Galvis, Oscar A / González Huezo, María S / Bessone, Fernando / Rocha, Tarciso D S / Fassio, Eduardo / Terra, Carlos / Marín, Juan I / Sierra Casas, Patricia / de la Peña-Ramirez, Carlos / Aguilar Parera, Ferran / Fernandes, Flavia / da Penha Zago-Gomes, Maria / Méndez-Guerrero, Osvely / Marciano, Sebastián / Mattos, Angelo A / Oliveira, Joao C / Guerreiro, Gabriel T S / Codes, Liana / Arrese, Marco / Nardelli, Mateus J / Silva, Marcelo O / Palma-Fernandez, Renato / Alcantara, Camila / Sánchez Garrido, Cristina / Trebicka, Jonel / Gustot, Thierry / Fernández, Javier / Clària, Joan / Jalan, Rajiv / Angeli, Paolo / Arroyo, Vicente / Moreau, Richard / Carrilho, Flair J

Gastroenterology

2023 Volume 165, Issue 3, Page(s) 696–716

Abstract: Background & aims: Genetic ancestry or racial differences in health outcomes exist in diseases associated with systemic inflammation (eg, COVID-19). This study aimed to investigate the association of genetic ancestry and race with acute-on-chronic liver ...

Abstract	Background & aims: Genetic ancestry or racial differences in health outcomes exist in diseases associated with systemic inflammation (eg, COVID-19). This study aimed to investigate the association of genetic ancestry and race with acute-on-chronic liver failure (ACLF), which is characterized by acute systemic inflammation, multi-organ failure, and high risk of short-term death. Methods: This prospective cohort study analyzed a comprehensive set of data, including genetic ancestry and race among several others, in 1274 patients with acutely decompensated cirrhosis who were nonelectively admitted to 44 hospitals from 7 Latin American countries. Results: Three hundred ninety-five patients (31.0%) had ACLF of any grade at enrollment. Patients with ACLF had a higher median percentage of Native American genetic ancestry and lower median percentage of European ancestry than patients without ACLF (22.6% vs 12.9% and 53.4% vs 59.6%, respectively). The median percentage of African genetic ancestry was low among patients with ACLF and among those without ACLF. In terms of race, a higher percentage of patients with ACLF than patients without ACLF were Native American and a lower percentage of patients with ACLF than patients without ACLF were European American or African American. In multivariable analyses that adjusted for differences in sociodemographic and clinical characteristics, the odds ratio for ACLF at enrollment was 1.08 (95% CI, 1.03-1.13) with Native American genetic ancestry and 2.57 (95% CI, 1.84-3.58) for Native American race vs European American race CONCLUSIONS: In a large cohort of Latin American patients with acutely decompensated cirrhosis, increasing percentages of Native American ancestry and Native American race were factors independently associated with ACLF at enrollment.
MeSH term(s)	Humans ; Latin America/epidemiology ; Liver Cirrhosis/diagnosis ; Liver Cirrhosis/epidemiology ; Liver Cirrhosis/genetics ; Prospective Studies ; COVID-19/complications ; Acute-On-Chronic Liver Failure/diagnosis ; Acute-On-Chronic Liver Failure/epidemiology ; Acute-On-Chronic Liver Failure/genetics ; Inflammation/complications ; Prognosis
Language	English
Publishing date	2023-05-30
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80112-4
ISSN	1528-0012 ; 0016-5085
ISSN (online)	1528-0012
ISSN	0016-5085
DOI	10.1053/j.gastro.2023.05.033
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ui V Zs.44: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 572: Show issues

Order via subito

Details ▾

Article ; Online: Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis.

Higuera-de la Tijera, Fátima / Servín-Caamaño, Alfredo I / Serralde-Zúñiga, Aurora E / Cruz-Herrera, Javier / Pérez-Torres, Eduardo / Abdo-Francis, Juan M / Salas-Gordillo, Francisco / Pérez-Hernández, José L

World journal of gastroenterology

2015 Volume 21, Issue 16, Page(s) 4975–4985

Abstract: Aim: To evaluate the impact of metadoxine (MTD) on the 3- and 6-mo survival of patients with severe alcoholic hepatitis (AH).: Methods: This study was an open-label clinical trial, performed at the "Hospital General de México, Dr. Eduardo Liceaga". ... ...

Abstract	Aim: To evaluate the impact of metadoxine (MTD) on the 3- and 6-mo survival of patients with severe alcoholic hepatitis (AH). Methods: This study was an open-label clinical trial, performed at the "Hospital General de México, Dr. Eduardo Liceaga". We randomized 135 patients who met the criteria for severe AH into the following groups: 35 patients received prednisone (PDN) 40 mg/d, 35 patients received PDN+MTD 500 mg three times daily, 33 patients received pentoxifylline (PTX) 400 mg three times daily, and 32 patients received PTX+MTD 500 mg three times daily. The duration of the treatment for all of the groups was 30 d. Results: In the groups treated with the MTD, the survival rate was higher at 3 mo (PTX+MTD 59.4% vs PTX 33.3%, P = 0.04; PDN+MTD 68.6% vs PDN 20%, P = 0.0001) and at 6 mo (PTX+MTD 50% vs PTX 18.2%, P = 0.01; PDN+MTD 48.6% vs PDN 20%, P = 0.003) than in the groups not treated with MTD. A relapse in alcohol intake was the primary independent factor predicting mortality at 6 mo. The patients receiving MTD maintained greater abstinence than those who did not receive it (74.5% vs 59.4%, P = 0.02). Conclusion: MTD improves the 3- and 6-mo survival rates in patients with severe AH. Alcohol abstinence is a key factor for survival in these patients. The patients who received the combination therapy with MTD were more likely to maintain abstinence than those who received monotherapy with either PDN or PTX.
MeSH term(s)	Adult ; Alcohol Abstinence ; Alcohol Deterrents/administration & dosage ; Alcohol Deterrents/adverse effects ; Drug Administration Schedule ; Drug Combinations ; Drug Therapy, Combination ; Female ; Glucocorticoids/administration & dosage ; Hepatitis, Alcoholic/diagnosis ; Hepatitis, Alcoholic/drug therapy ; Hepatitis, Alcoholic/mortality ; Humans ; Kaplan-Meier Estimate ; Male ; Mexico ; Middle Aged ; Pentoxifylline/administration & dosage ; Prednisone/administration & dosage ; Proportional Hazards Models ; Pyridoxine/administration & dosage ; Pyridoxine/adverse effects ; Pyrrolidonecarboxylic Acid/administration & dosage ; Pyrrolidonecarboxylic Acid/adverse effects ; Risk Factors ; Severity of Illness Index ; Survival Rate ; Time Factors ; Treatment Outcome
Chemical Substances	Alcohol Deterrents ; Drug Combinations ; Glucocorticoids ; metadoxine (EJQ7M98H5J) ; Pyridoxine (KV2JZ1BI6Z) ; Pentoxifylline (SD6QCT3TSU) ; Pyrrolidonecarboxylic Acid (SZB83O1W42) ; Prednisone (VB0R961HZT)
Language	English
Publishing date	2015-04-28
Publishing country	United States
Document type	Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	2185929-2
ISSN	2219-2840 ; 1007-9327
ISSN (online)	2219-2840
ISSN	1007-9327
DOI	10.3748/wjg.v21.i16.4975
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Zs.A 6039: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis.

Higuera-de la Tijera, Fátima / Servín-Caamaño, Alfredo I / Cruz-Herrera, Javier / Serralde-Zúñiga, Aurora E / Abdo-Francis, Juan M / Gutiérrez-Reyes, Gabriela / Pérez-Hernández, José L

Annals of hepatology

2014 Volume 13, Issue 3, Page(s) 343–352

Abstract: Background & aim: Despite treatment with glucocorticoids, mortality remains high in patients with severe alcoholic hepatitis. Oxidative stress and depletion of mitochondrial glutathione are implicated factors in liver injury. The aim of this study was ... ...

Abstract	Background & aim: Despite treatment with glucocorticoids, mortality remains high in patients with severe alcoholic hepatitis. Oxidative stress and depletion of mitochondrial glutathione are implicated factors in liver injury. The aim of this study was to evaluate the impact of the addition of metadoxine, a drug which possesses a multifactorial mechanism of action, including antioxidant properties, to standard treatment with glucocorticoids in patients with severe alcoholic hepatitis. Material and methods: This randomized open label clinical trial was performed in Mexico's General Hospital (Registry Key DIC/10/107/03/043). We randomized 70 patients with severe alcoholic hepatitis. The first group received prednisone (40 mg/day), and the second group received prednisone (40 mg/day) plus metadoxine tablets (500 mg three times daily). The duration of treatment in both groups was 30 days. Survival at 30 and 90 days, development of complications, adverse events and response to treatment (Lille model) were assessed. Results: In the group receiving metadoxine, significant improvements were observed, as follows: survival at 30 days (74.3 vs. 45.7%, P = 0.02); survival at 90 days (68.6 vs. 20.0%, P = 0.0001). There was less development or progression of encephalopathy (28.6 vs. 60.0%, P = 0.008) and hepatorenal syndrome (31.4 vs. 54.3%, P = 0.05), and the response to treatment (Lille model) was higher in the metadoxine group (0.38 vs. 0.63, P = 0.001; 95% CI 0.11 to 0.40). There were no differences between groups regarding the development or progression of variceal hemorrhage or infection. The incidence of adverse events, mainly gastrointestinal, was similar in both groups. Conclusions: Addition of metadoxine to glucocorticoid treatment improves the short-term survival of patients with severe alcoholic hepatitis and diminishes the development or progression of encephalopathy and hepatorenal syndrome.
MeSH term(s)	Adult ; Aged ; Alcohol Deterrents/therapeutic use ; Antioxidants/therapeutic use ; Drug Combinations ; Drug Therapy, Combination ; Esophageal and Gastric Varices/drug therapy ; Esophageal and Gastric Varices/etiology ; Esophageal and Gastric Varices/prevention & control ; Female ; Gastrointestinal Hemorrhage/etiology ; Gastrointestinal Hemorrhage/prevention & control ; Glucocorticoids/therapeutic use ; Hepatic Encephalopathy/drug therapy ; Hepatic Encephalopathy/etiology ; Hepatic Encephalopathy/prevention & control ; Hepatitis, Alcoholic/complications ; Hepatitis, Alcoholic/drug therapy ; Hepatitis, Alcoholic/mortality ; Hepatorenal Syndrome/drug therapy ; Hepatorenal Syndrome/etiology ; Hepatorenal Syndrome/prevention & control ; Humans ; Male ; Middle Aged ; Prednisone/therapeutic use ; Pyridoxine/therapeutic use ; Pyrrolidonecarboxylic Acid/therapeutic use ; Severity of Illness Index ; Treatment Outcome
Chemical Substances	Alcohol Deterrents ; Antioxidants ; Drug Combinations ; Glucocorticoids ; metadoxine (EJQ7M98H5J) ; Pyridoxine (KV2JZ1BI6Z) ; Pyrrolidonecarboxylic Acid (SZB83O1W42) ; Prednisone (VB0R961HZT)
Language	English
Publishing date	2014-04-17
Publishing country	Mexico
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	2188733-0
ISSN	1665-2681
ISSN	1665-2681
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6221: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Search results

Search options

Article ; Online: Impact of COVID-19 on pre-existing liver disease.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: PROTON PUMP INHIBITORS INCREASE THE OVERALL RISK OF DEVELOPING BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: The Age-AST-D Dimer (AAD) Regression Model Predicts Severe COVID-19 Disease.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America.

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis.

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article: Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito